010 QUANTIFYING THE ASSOCIATION BETWEEN MORTALITY AND CHANGE IN ACE INHIBITOR AND Β-Blocker DOSE IN PATIENTS WITH CHRONIC HEART FAILURE: A PROSPECTIVE COHORT STUDY

Abstract

Background Dose escalation of evidence-based chronic heart failure pharmacotherapy in real-life does not approach that achieved in clinical trials; it is unclear whether this impacts upon mortality. We aimed to quantify the association between temporal changes in β-adrenoceptor antagonist (β-blocker) and ACE inhibitor (ACEI) dose and mortality in patients with chronic heart failure.